The Development of Biocatalysis as a Tool for Drug Discovery

被引:14
作者
Schwarz, Jenny [1 ]
Rosenthal, Katrin [1 ]
Snajdrova, Radka [2 ]
Kittelmann, Matthias [3 ]
Lutz, Stephan [1 ]
机构
[1] TU Dortmund Univ, Chair Bioproc Engn, Emil Figge Str 66, D-44227 Dortmund, Germany
[2] Novartis Pharma AG, Global Discovery Chem, Lichtstr, CH-4056 Basel, Switzerland
[3] Novartis Pharma AG, Inst BioMed Res, Lichtstr, CH-4056 Basel, Switzerland
关键词
Biocatalysis; Chiral building blocks; Drug metabolites; Natural product modifications; Pharmacological activity; ENZYMATIC-SYNTHESIS; CHEMOENZYMATIC SYNTHESIS; ESCHERICHIA-COLI; ALDEHYDE OXIDASE; AMIDOHYDROLASE; RECOMBINANT; METABOLISM; ENZYMES; REGENERATION; PURIFICATION;
D O I
10.2533/chimia.2020.368
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Enzymes are versatile biocatalysts capable of performing selective reactions. The advantages of enzymes in comparison to classical chemistry including chemical catalysts are the generally milder process conditions and avoidance of harmful reactants. Their high selectivity and specificity are especially beneficial for the enzymatic synthesis of new products with potential applications in drug research. Therefore, in the past decades, the utilization of isolated enzymes or whole-cell biocatalysts has spread through a growing number of biotechnological industries. The applications comprise the production of chiral building blocks for the pharmaceutical and fine chemical industry, the enzymatic synthesis of drug metabolites for testing of toxicity, function, biological activity, degradation and the production of biocatalytically modified natural products, which all play a role in drug discovery. Especially Oreste Ghisalba's contributions, which paved the way for the industrial use of enzymes, will be considered in this review.
引用
收藏
页码:368 / 377
页数:10
相关论文
共 73 条
  • [11] Danysz W., 1995, Drug News Perspect, V8, P261
  • [12] The role of drug metabolizing enzymes in clearance
    Di, Li
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (03) : 379 - 393
  • [13] Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes
    Di Nardo, Giovanna
    Fantuzzi, Andrea
    Sideri, Anastasia
    Panicco, Paola
    Sassone, Carlo
    Giunta, Carlo
    Gilardi, Gianfranco
    [J]. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2007, 12 (03): : 313 - 323
  • [14] Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014-2019)
    Dominguez de Maria, Pablo
    de Gonzalo, Gonzalo
    Alcantara, Andres R.
    [J]. CATALYSTS, 2019, 9 (10)
  • [15] SYNTHESIS OF (R)-TERT-LEUCINOL BY CLASSICAL RESOLUTION OF THE RACEMIC-MIXTURE
    DRAUZ, K
    JAHN, W
    SCHWARM, M
    [J]. CHEMISTRY-A EUROPEAN JOURNAL, 1995, 1 (08) : 538 - 540
  • [16] Improving catalytic function by ProSAR-driven enzyme evolution
    Fox, Richard J.
    Davis, S. Christopher
    Mundorff, Emily C.
    Newman, Lisa M.
    Gavrilovic, Vesna
    Ma, Steven K.
    Chung, Loleta M.
    Ching, Charlene
    Tam, Sarena
    Muley, Sheela
    Grate, John
    Gruber, John
    Whitman, John C.
    Sheldon, Roger A.
    Huisman, Gjalt W.
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (03) : 338 - 344
  • [17] Cladosporin Derivatives Obtained by Biotransformation Provide Guidance for the Focused Derivatization of this Antimalarial Lead Compound
    Fredenhagen, Andreas
    Schroer, Kirsten
    Schroeder, Harald
    Hoepfner, Dominic
    Ligibel, Mathieu
    Zemp, Liliane Porchet
    Radoch, Caroline
    Freund, Ernst
    Meishammer, Aldo
    [J]. CHEMBIOCHEM, 2019, 20 (05) : 650 - 654
  • [18] Gauss D, 2016, APPL BIOCATALYSIS FU, P147, DOI DOI 10.1002/9783527677122.CH8
  • [19] Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis
    Geier, Martina
    Bachler, Thorsten
    Hanlon, Steven P.
    Eggimann, Fabian K.
    Kittelmann, Matthias
    Weber, Hansjoerg
    Luetz, Stephan
    Wirz, Beat
    Winkler, Margit
    [J]. MICROBIAL CELL FACTORIES, 2015, 14
  • [20] Ghisalba O., 2007, MODERN BIOOXIDATION, P214